Related Experiment Video
Updated: May 29, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Current treatment of locally advanced and metastatic prostate cancer]
Anton Ponholzer1, Ferdinand Steinbacher, Stephan Madersbacher
1Abteilung für Urologie und Andrologie, Krankenhaus der Barmherzigen Brüder, Wien, Austria. antonponholzer@hotmail.com
Abstract:
Despite the broad use of PSA-testing in western medicine, still an estimated 1/3 of carcinomas of the prostate (PC) are diagnosed in a locally advanced or metastatic stage. In the current treatment-algorithm for locally advanced PC, radical prostatectomy, external beam radiation therapy (with and without hormonal therapy) and primary androgen deprivation are available. In fact, in a majority of patients treatment of this tumor stage will be a multimodal approach, which has to be discussed individually. For metastatic PC hormonal deprivation therapy is still the gold standard. Beside LHRH-agonists, surgical castration and complete androgen deprivation today LHRH-antagonists represent the different therapeutic options in this tumor stage. Effects on natural course of this disease have to be balanced to the side effects of long-term therapy. Castration-resistant PC is not the object of this overview even though there are a variety of new medical interventions emerging for the treatment of this stage of PC.
Related Concept Videos
Treatment Resistent Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers

